Stockscreener 앱 받기
19.74
2.28%
-0.46
전일 마감가:
$20.20
열려 있는:
$20.19
하루 거래량:
1.43M
Relative Volume:
0.54
시가총액:
$2.18B
수익:
$70.92M
순이익/손실:
$-342.21M
주가수익비율:
-5.2439
EPS:
-3.7644
순현금흐름:
$-304.30M
1주 성능:
+1.75%
1개월 성능:
+25.17%
6개월 성능:
-37.83%
1년 성능:
+15.24%
1일 변동 폭
$19.32
$20.19
1주일 범위
$18.80
$20.88
52주 변동 폭
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
명칭
Viridian Therapeutics Inc
전화
617.272.4600
주소
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
19.74 | 2.18B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 재확인 | Wedbush | Outperform |
| 2025-12-03 | 개시 | William Blair | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 개시 | TD Cowen | Buy |
| 2024-09-11 | 재확인 | Needham | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-05-09 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 개시 | BTIG Research | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-05-30 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-17 | 개시 | Wells Fargo | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2022-12-19 | 개시 | Cowen | Outperform |
| 2022-12-19 | 개시 | Needham | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-12-01 | 개시 | H.C. Wainwright | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-11-18 | 개시 | SVB Leerink | Outperform |
| 2021-10-12 | 개시 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Price-Driven Insight from (VRDN) for Rule-Based Strategy - Stock Traders Daily
Tangible book value per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Operating cash flow per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Viridian Therapeutics outlines eye disease strategy as Nasdaq-listed biotech builds its pipeline - ad-hoc-news.de
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - AOL.com
Viridian Therapeutics updates pipeline plans as thyroid eye disease program advances - AD HOC NEWS
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone - Yahoo Finance
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease - Sahm
VRDNViridian Therapeutics Inc Options - Finviz
If You Invested $1,000 in Viridian Therapeutics Inc (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 stock options at $18.48 strike - Stock Titan
Viridian Therapeutics (VRDN) director-linked funds receive 32,341 options - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 options at $18.48 - Stock Titan
Fairmount-linked entities receive 32,341 Viridian (VRDN) stock options at $18.48 - Stock Titan
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know - The Globe and Mail
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more - Medical Marketing and Media
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-07-01 - Seeking Alpha
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30 - Moomoo
VRDN Maintained by Needham -- Price Target Raised to $34.00 - GuruFocus
FDA clears Viridian's veligrotug for TED as Lumvoa - Eyes On Eyecare
RBC Lifts Price Target on Viridian Therapeutics to $35 From $34, Keeps Outperform, Speculative Risk - Moomoo
VRDN Maintained by RBC Capital -- Price Target Raised to $35.00 - GuruFocus
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says - marketscreener.com
VRDN Maintained by Truist Securities -- Price Target Raised to $38 - GuruFocus
VRDN Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43 - Moomoo
Viridian Therapeutics | SCHEDULE 13G: Others - Moomoo
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval (NASDAQ:VRDN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE) - The Globe and Mail
Viridian Therapeutics Receives FDA Approval for Lumvoa for the Treatment of Thyroid Eye Disease (TED) - VisionMonday.com
Viridian launches first commercial product as US approves thyroid eye disease therapy - MSN
VRDN Upgraded by Wells Fargo -- Price Target Raised to $31 - GuruFocus
UBS reiterates Viridian Therapeutic stock rating on FDA approval By Investing.com - Investing.com Australia
Wedbush raises Viridian Therapeutic stock price target to $43 - Investing.com
Wedbush raises Viridian Therapeutic stock price target to $43 By Investing.com - Investing.com Canada
Viridian Therapeutic stock rating reiterated at Outperform by William Blair - Investing.com Canada
(VRDN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
New Viridian meridian? Hopes veli high in TED post-FDA win - BioWorld News
Wells Fargo Upgrades Viridian Therapeutics to Overweight From Equalweight - Moomoo
Viridian Therapeutics (VRDN) Receives Upgrade from Wells Fargo - GuruFocus
Wells Fargo Upgrades Viridian Therapeutics(VRDN.US) to Buy Rating, Raises Target Price to $31 - Moomoo
Citizens reiterates Viridian stock rating on FDA drug approval - Investing.com UK
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Benzinga
VRDN Reiterated by Needham -- Price Target Maintained at $32 - GuruFocus
Viridian Therapeutic stock gets FDA approval for thyroid eye disease drug - Investing.com Canada
Comcast, Viridian Therapeutics jump premarket; Doximity slips By Investing.com - Investing.com Canada
Viridian Therapeutics (VRDN) Soars 12% Following FDA Approval of Lumvoa - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595) - The Globe and Mail
Viridian Therapeutics Inc (VRDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):